Covina, CA, June 17, 2021 (GLOBE NEWSWIRE) -- The global Mucormycosis treatment market accounted for US$ 399.7 Million in 2020 and is estimated to be US$ 822.0 Million by 2030 and is anticipated to register a CAGR of 7.5 %. Mucormycosis is a life-threatening invasive fungal disease that, despite treatment, has a high rate of morbidity and mortality. Mucormycosis can manifest in a variety of ways in humans, especially in immunocompromised patients and diabetics. Infections of the rhino-orbital-cerebral and pulmonary systems are the most common syndromes caused by these fungi. Mucormycosis is a fungus caused by the mucormycetes, a group of moulds. Additionally, inhaling fungal spores can damage the lungs and sinuses, and the disease can penetrate the body through wounds such as cuts, scrapes, burns, or other forms of skin trauma.
Request a Free Sample Copy of this Business Intelligence Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/4691
The report " Global Mucormycosis Treatment Market, By Species (Cunninghamella, Saksenaea, Rhizopus, Rhizomucor, mucor, Lichtheimia, Apophysomyces and others), By Diagnosis method (Computed Tomography, Magnetic Resonance Imaging, Tissue Biopsy and others.), By Treatment (Amphotericin B therapy, Antifungal medication, surgery, and others), By End-user, (hospitals, clinics, research organization, medical institute and others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030”
Key Highlights:
- European governments have introduced incentive programs to promote the anti-infective drug industry while also lowering risk and cost for manufacturers.
- In 2021, Bharat Serums & Vaccines (BSV) is the first Indian company to receive approval from the Drugs Controller General of India (DCGI) for Liposomal Amphotericin B, an antifungal medicine used to treat mucormycosis.
Ask for a Discount on the Current Pricing @ https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/4691
Analyst View:
The mucormycosis market is being driven by an increase in the prevalence of fungal infections, an increase in the incidence of immunological diseases, and greater access to a wide range of drugs. Furthermore, an increasing geriatric population, increased government spending, and the healthcare expenditure have all contributed to the market's rise. Treatment side effects and the presence of misbranded and counterfeit products, on the other hand, may stifle market development. The rising number of diabetic patients, especially in Europe's developed countries, is another factor driving the mucormycosis market.
Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Global Mucormycosis Treatment Market, By Species (Cunninghamella, Saksenaea, Rhizopus, Rhizomucor, mucor, Lichtheimia, Apophysomyces and others), By Diagnosis method (Computed Tomography, Magnetic Resonance Imaging, Tissue Biopsy and others.), By Treatment (Amphotericin B therapy, Antifungal medication, surgery, and others), By End-user, (hospitals, clinics, research organization, medical institute and others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030”
To know the upcoming trends and insights prevalent in this market, click the link below:
https://www.prophecymarketinsights.com/market_insight/Global-Mucormycosis-Treatment-Market-4691
Key Market Insights from the report:
The global Mucormycosis treatment market accounted for US$ 399.7 Million in 2020 and is estimated to be US$ 822.0 Million by 2030 and is anticipated to register a CAGR of 7.5 %.The Global Mucormycosis Treatment Market is segmented based on the Species, diagnosis method,, treatment, end-user, and region.
- By species, the Global Mucormycosis treatment Market is segmented into Cunninghamella, Saksenaea, Rhizopus, Rhizomucor, mucor, Lichtheimia, Apophysomyces and others
- By Diagnosis method, the market is segmented in Computed Tomography, Magnetic Resonance Imaging, Tissue Biopsy and others
- By Treatment, the Global Mucormycosis treatment Market is segmented into Amphotericin B therapy, Antifungal medication, surgery, and others
- By End-user, the market is segmented into hospitals, clinics, research organization, medical institute and others
- By region, the Global Mucormycosis treatment Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Competitive Landscape:
The key players operating in the global mucormycosis treatment market includes Abbott Laboratories, Biocon Limited, Cadila Pharmaceuticals Limited, Novartis AG, F. Hoffman La Roche, Merck Sharp and Dohme, Mylan Labs, Bristol Myers Squibb, Bayer AG, Lonza Group, Sanofi, Johnson & Johnson, Pfizer Inc., and Gilead Sciences.
The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.
About Prophecy Market Insights
Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.
Some Important Points Answered in this Market Report Are Given Below:
- Explains an overview of the product portfolio, including product development, planning, and positioning
- Explains details about key operational strategies with a focus on R&D strategies, corporate structure, localization strategies, production capabilities, and financial performance of various companies.
- Detailed analysis of the market revenue over the forecasted period.
- Examining various outlooks of the market with the help of Porter’s five forces analysis, PEST & SWOT Analysis.
- Study on the segments that are anticipated to dominate the market.
- Study on the regional analysis that is expected to register the highest growth over the forecast period
Key Topics Covered
- Introduction
- Study Deliverables
- Study Assumptions
- Scope of the Study
- Research Methodology
- Executive Summary
- Opportunity Map Analysis
- Market at Glance
- Market Share (%) and BPS Analysis, by Region
- Competitive Landscape
- Heat Map Analysis
- Market Presence and Specificity Analysis
- Investment Analysis
- Competitive Analysis
Browse Related Reports: